Koers Aoxing Pharmaceutical Company Inc Nyse
Aandelen
US03740A1060
Farmaceutische producten
Omzet 2015 | 25,48 mln. 23,91 mln. | Omzet 2016 | 32,33 mln. 30,34 mln. | Marktkapitalisatie | 49,54 mln. 46,49 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2015 | 5 mln. 4,69 mln. | Nettowinst (verlies) 2016 | 2 mln. 1,88 mln. | EV/omzet 2015 | 5,77 x |
Nettoschuld 2015 | 24,8 mln. 23,28 mln. | Nettoschuld 2016 | 18,56 mln. 17,42 mln. | EV/omzet 2016 | 2,11 x |
K/w-verhouding 2015 |
20,1
x | K/w-verhouding 2016 |
23,2
x | Werknemers | - |
Dividendrendement 2015 * |
-
| Dividendrendement 2016 |
-
| Vrij verhandelbaar | 100% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
David Duarte
CEO | Chief Executive Officer | - | 11-08-23 |
Gui Rong Zhou
CTO | Chief Tech/Sci/R&D Officer | 69 | 01-01-11 |
Peng Jiang
SAM | Sales & Marketing | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
David Duarte
CEO | Chief Executive Officer | - | 11-08-23 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+19,27% | 43,18 mld. | |
+24,37% | 23,23 mld. | |
+15,11% | 14,6 mld. | |
+12,33% | 13,54 mld. | |
+38,36% | 11,5 mld. | |
-7,65% | 6,79 mld. | |
-0,05% | 6,79 mld. | |
-8,87% | 5,73 mld. | |
+10,21% | 5,31 mld. |